Certolizumab pegol for the treatment of Crohn’s disease

Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Tumour Necrosis Factor-Alpha Antagonist Therapy in Crohn’s Disease

(2016) Daniel C Sadowski et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab

(2011) B. G. Feagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease

(2010) S. B. Hanauer et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn’s disease in the PRECiSE 2 study

(2010) B. G. FEAGAN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

(2010) S. Lichtiger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study

(2010) S. Schreiber et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease

(2010) H.-C. REINECKER et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine

(2010) T. T. MACDONALD et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study

(2010) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months

(2010) Gary R. Lichtenstein et al.   Clinical Gastroenterology and Hepatology

W1208 No Significant Transfer of Certolizumab Pegol Compared With IgG in the Perfused Human Placenta In Vitro

(2010) Charlene Porter et al.   GASTROENTEROLOGY

44 Patients With Crohn's Disease Treated With Certolizumab Pegol Experienced Long-Term Remission Regardless of Prior TNF-α Inhibitor Exposure (PRECiSE 4 Study)

(2010) William J. Sandborn et al.   GASTROENTEROLOGY

S1045 Endoscopic Mucosal Improvement in Patients With Active Crohn's Disease Treated With Certolizumab Pegol: Week 10 and 54 Results of the Music Trial

(2010) Jean-Frederic Colombel et al.   GASTROENTEROLOGY

The potential for disease modification in Crohn's disease

(2010) G. Van Assche et al.   Nature Reviews Gastroenterology & Hepatology

Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn’s fistulas

(2009) S. C. NG et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinically Meaningful Improvement in Health-Related Quality of Life in a Randomized Controlled Trial of Certolizumab Pegol Maintenance Therapy for Crohn's Disease

(2009) Brian G Feagan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Serum Levels of Interleukin-10 and Interleukin-12 Predict Early, Spontaneous Hepatitis B Virus e Antigen Seroconversion

(2009) Jia–Feng Wu et al.   GASTROENTEROLOGY

World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010

(2009) Charles N. Bernstein et al.   INFLAMMATORY BOWEL DISEASES

How to manage difficult Crohn’s disease: optimum delivery of anti-TNFs

(2009) Darin S Krygier et al.   Expert Review of Gastroenterology & Hepatology

In Patients With Slow Transit Constipation, the Pattern of Colonic Transit Delay Does Not Differentiate Between Those With and Without Impaired Rectal Evacuation

(2008) Natalie Zarate et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

(2008) J Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

(2008) R Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

(2008) Edward Keystone et al.   ARTHRITIS AND RHEUMATISM

A PEGylated Fab′ Fragment against Tumor Necrosis Factor for the Treatment of Crohn Disease

(2008) Tim Bourne et al.   BIODRUGS

The Impact of PEGylation on Biological Therapies

(2008) Francesco M Veronese et al.   BIODRUGS

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease

(2008) Margaret C. Reilly et al.   CLINICAL THERAPEUTICS

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET